A NHS vaccinator administers the Pfizer-BioNTech Covid-19 booster jab to a woman, at a vaccination centre in London. BioNTech is launching a large-scale trial of mRNA therapies to treat cancer and other diseases in the U.K.
Sopa Images | Lightrocket | Getty Images
LONDON — The U.K. government on Friday announced a partnership with German firm BioNTech to test potential vaccines for cancer and other diseases, as campaigners warned any breakthrough must remain affordable and accessible.
Cancer patients in England will get early access to trials involving personalized mRNA therapies, including cancer vaccines, which aim to spur the immune system to attack harmful cells.
BioNTech said it will set up a new research and development center in the U.K. and deliver 10,000 therapies to patients from September 2023 until the end of the decade.
The company developed one of the most widely-distributed Covid-19 vaccines alongside U.S. pharma firm Pfizer. Its CEO, Ugur Sahin, said it had learned lessons from the coronavirus pandemic about collaboration between the British National Health Service, academics, regulators and the private sector in the development of drugs that it was applying now.
“Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years,” he said in a statement. “The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide.”
Peter Johnson, Britain’s National Clinical Director for Cancer, said mRNA technology had the potential to transform approaches to a number of illnesses.
Other mRNA cancer vaccines, including a collaboration between U.S. firms Moderna and Merck, are also being trialed.
Tim Bierley, a campaigner at U.K.-based group Global Justice Now, said big pharmaceutical companies had “terrible record of price gouging on new medicines, even where public money has played a key role in bringing them to the market.”
“The government has a moral duty to push BioNtech to set the price of this potentially life-saving vaccine so it is accessible to all,” he said.
Mohga Kamal-Yanni, policy co-lead for the People’s Vaccine Alliance — a global group of health organizations, economists and activists — said news of the trial was good, but that any outcome “belongs to the people” due to the amount of public funding involved.
“The U.K. government must say how it will ensure any new medicine, vaccine or technology will be made available and affordable to developing countries,” Kamal-Yanni said.
CNBC has contacted the U.K. Department of Health and Social Care for a response.
